Neil Desai, Aadi Bioscience CEO (via YouTube)
Precision oncology biotech agrees to $72M cash infusion as it seeks to increase revenue
Almost a year after the FDA gave the green light to LA-based Aadi Bioscience’s first drug, the biotech is looking to private investors to keep …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
